Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En effekt- och säkerhetsstudie av ALZ-801 i APOE4/4 tidiga AD-ämnen (APOLLOE4)

3 september 2026 uppdaterad av: Alzheon Inc.

En fas 3, multicenter, randomiserad, dubbelblind, placebokontrollerad studie av effektivitet, säkerhet och biomarköreffekter av ALZ-801 hos personer med tidig Alzheimers sjukdom och genotyp APOE4/4

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

Studieöversikt

Detaljerad beskrivning

This is a multi-center, double-blind study that will evaluate 265 mg twice daily (BID) of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.

Studietyp

Interventionell

Inskrivning (Faktisk)

325

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Marseille, Frankrike, 13385
        • Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
      • Montpellier, Frankrike, 43431
        • Hopital Gui de Chauliac - CHRU de Montpellier
      • Paris, Frankrike, 75475
        • Hopital Lariboisiere - Fernand-Widal - AP-HP
      • Rouen, Frankrike, 76031
        • Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen
      • Strasbourg, Frankrike, 67200
        • Hopitaux Universitaires de Strasbourg Centre d'Investigation Clinique
      • Toulouse, Frankrike, 31059
        • Centre de Recherche Clinique du Gerontopole - CHU Toulouse
      • Villeurbanne, Frankrike, 69100
        • Centre de Recherche-Hopital Geriatrique de Charpennes
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85004
        • Xenoscience
      • Scottsdale, Arizona, Förenta staterna, 85297
        • CCT Research
      • Sun City, Arizona, Förenta staterna, 85351
        • Banner Sun Health Research Institute
    • California
      • Costa Mesa, California, Förenta staterna, 92626
        • ATP Clinical Research
      • Irvine, California, Förenta staterna, 92780
        • Tilda Research
      • La Jolla, California, Förenta staterna, 92037
        • UCSD Shiley-Marcos Alzheimer's Disease Research Center
      • Lomita, California, Förenta staterna, 90717
        • Torrance Clinical Research Institute
      • Long Beach, California, Förenta staterna, 90806
        • Collaborative NeuroScience Network LLC
      • Palo Alto, California, Förenta staterna, 94304
        • Stanford University
      • Pasadena, California, Förenta staterna, 91105
        • SC3 Research Group
      • Sacramento, California, Förenta staterna, 95816
        • Sutter Health
    • Florida
      • Atlantis, Florida, Förenta staterna, 33462
        • JEM Research Institute, Headlands Site
      • Bradenton, Florida, Förenta staterna, 34205
        • Bradenton Research Center
      • Hialeah, Florida, Förenta staterna, 33016
        • Galiz Research
      • Jupiter, Florida, Förenta staterna, 33458
        • Alphab Global Research
      • Lady Lake, Florida, Förenta staterna, 32159
        • Charter Research
      • Maitland, Florida, Förenta staterna, 32751
        • K2 Medical Research, LLC
      • Miami, Florida, Förenta staterna, 33137
        • Miami Jewish Health
      • Miami, Florida, Förenta staterna, 33144
        • Y & L Advance Health Care, Inc /DBA Elite Clinical Research
      • Miami Beach, Florida, Förenta staterna, 33140
        • Mount Sinai Medical Center
      • Naples, Florida, Förenta staterna, 34105
        • Aqualane Clinical Research
      • Orlando, Florida, Förenta staterna, 32819
        • Headlands Research Orlando
      • Orlando, Florida, Förenta staterna, 32803
        • Charter Research
      • Palm Beach Gardens, Florida, Förenta staterna, 33410
        • Advanced Research Consultants
      • Pompano Beach, Florida, Förenta staterna, 33064
        • Quantum CNS Clinical Research
      • Port Orange, Florida, Förenta staterna, 32127
        • Progressive Medical Research
      • Stuart, Florida, Förenta staterna, 34997
        • ALZ Research and Treatment Center (A.R.T.C.)
      • Wellington, Florida, Förenta staterna, 33414
        • ALZ Research and Treatment Center (A.R.T.C.)
      • West Palm Beach, Florida, Förenta staterna, 33407
        • Premiere Research Institute
    • Georgia
      • Columbus, Georgia, Förenta staterna, 31909
        • Columbus Memory Center
      • Decatur, Georgia, Förenta staterna, 30030
        • Sandhill Research, LLC
    • Indiana
      • Fort Wayne, Indiana, Förenta staterna, 46804
        • Fort Wayne Neurological Center
    • Louisiana
      • Shreveport, Louisiana, Förenta staterna, 71103
        • Louisiana State University Health Sciences Center (LSUHSC)
    • Massachusetts
      • Plymouth, Massachusetts, Förenta staterna, 02360
        • Headlands Research Eastern MA
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89106
        • WR-CRCN
    • New Jersey
      • Toms River, New Jersey, Förenta staterna, 08755
        • Advanced Memory Research Center
    • New York
      • Albany, New York, Förenta staterna, 12208
        • Neurological Associates of Albany
      • New York, New York, Förenta staterna, 10016
        • NYU Alzheimer's Disease Research Center
      • Orangeburg, New York, Förenta staterna, 10962
        • Kline Institute for Psychiatric Research
      • Rochester, New York, Förenta staterna, 14620
        • University of Rochester Medical Center
      • Staten Island, New York, Förenta staterna, 10312
        • Richmond Behavioral Associates
    • North Carolina
      • Greensboro, North Carolina, Förenta staterna, 27410
        • Triad Clinical Trials
      • Matthews, North Carolina, Förenta staterna, 28105
        • AMC Research
    • Ohio
      • Canton, Ohio, Förenta staterna, 44718
        • NeuroScience Research Center
      • Dayton, Ohio, Förenta staterna, 45459
        • Neurology Diagnostics, Inc.
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73106
        • IPS Research
    • Oregon
      • Portland, Oregon, Förenta staterna, 97225
        • Center for Cognitive Health
    • Pennsylvania
      • Abington, Pennsylvania, Förenta staterna, 19001
        • Abington Neurological Associates
      • Allentown, Pennsylvania, Förenta staterna, 18104
        • Lehigh Center for Clinical Research
    • Rhode Island
      • East Providence, Rhode Island, Förenta staterna, 02914
        • Rhode Island Mood & Memory Research Institute
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37212
        • Vanderbilt Center for Cognitive Medicine
    • Texas
      • Houston, Texas, Förenta staterna, 77054
        • UT Health Science Center at Houston
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
        • Re:Cognition Health
    • Washington
      • Bellevue, Washington, Förenta staterna, 98007
        • Northwest Clinical Research Center
    • Wisconsin
      • Milwaukee, Wisconsin, Förenta staterna, 53226
        • Medical College of Wisconsin
      • Reykjavik, Island, 101
        • Memory Clinic, Landspitali University Hospital
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3S 1N2
        • Centricity Research
      • New Minas, Nova Scotia, Kanada, B4N 3R7
        • Centricity Research
    • Ontario
      • Ottawa, Ontario, Kanada, K1Z 1G3
        • Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
      • Peterborough, Ontario, Kanada, K9H 2P4
        • Kawartha Centre - Redefining Healthy Aging
      • Toronto, Ontario, Kanada, M3B 2S7
        • Toronto Memory Program
    • Quebec
      • Gatineau, Quebec, Kanada, J8T 8J1
        • Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais
      • 's-Hertogenbosch, Nederländerna, 5223 LA
        • Brain Research Center Den Bosch
      • Amsterdam, Nederländerna, 1081 GN
        • Brain Research Center Amsterdam
      • Zwolle, Nederländerna, 8025 AZ
        • Brain Research Center Zwolle
      • Barcelona, Spanien, 08028
        • Fundacia ACE - Institut Catala de Neurociencies Aplicadas
      • Madrid, Spanien, 28040
        • Hospital Clinico San Carlos
      • Madrid, Spanien, 28027
        • Clinica Universidad de Navarra
      • Pamplona, Spanien, 31008
        • Clinica Universidad de Navarra
      • Terrassa, Spanien, 08221
        • Hospital Universitari MutuaTerrassa
      • Valencia, Spanien, 46017
        • Centro Hospital Universitario Dr. Preset
      • Bristol, Storbritannien, BS32 4SY
        • Re:Cognition Health Ltd Bristol
      • London, Storbritannien, EC2Y 8EA
        • St. Pancras Clinical Research
      • Winchester, Storbritannien, SO21 1HU
        • Re-Cognition Health Ltd Winchester
    • Devon
      • Plymouth, Devon, Storbritannien, PL6 8BT
        • Re-Cognition Health Ltd Plymouth
    • Greater London
      • London, Greater London, Storbritannien, W1G 9JF
        • Re-Cognition Health Ltd London
    • North Lanarkshire
      • Motherwell, North Lanarkshire, Storbritannien, ML1 4UF
        • NeuroClin Glasgow Ltd
    • Surrey
      • Guildford, Surrey, Storbritannien, GU2 7YD
        • Re-Cognition Health Ltd Guildford
    • West Midlands
      • Birmingham, West Midlands, Storbritannien, B16 8LT
        • Re-Cognition Health Ltd Birmingham
      • Brno, Tjeckien, 656 91
        • Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
      • Brno, Tjeckien, 602 00
        • Medica 111, Spol. s r.o. - Neurologicka a Rehabilitacni Ambulance Brno, Centralni Pracoviste v Brne
      • Prague, Tjeckien, 160 00
        • Neuropsychiatrie s.r.o.
      • Rychnov nad Kněžnou, Tjeckien, 51601
        • Vestra Clinics - Dedicated Research Clinics
      • Aachen, Tyskland, 52074
        • University Hospital RWTH Aachen Neurological Study Center
      • München, Tyskland, 80336
        • Klinikum der Universitaet Muenchen Innenstadt
      • Tübingen, Tyskland, 72076
        • Universitätsklinik fuer Psychiatrie und Psychotherapie
      • Westerstede, Tyskland, 26655
        • Studienzentrum Nord-West

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

50 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
  • Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
  • MMSE score at Screening of 22 to 30 (inclusive).
  • CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
  • RBANS delayed memory index score ≤ 85.
  • Evidence of progressive memory loss over the last 12 months per investigator assessment

Exclusion Criteria:

  • Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.
  • Diagnosis of neurodegenerative disorder other than AD.
  • Diagnosis of major depressive disorder (MDD) within one year prior to screening.
  • Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.
  • History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
  • History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years).
  • Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: ALZ-801

ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one tablet of ALZ-801 265 mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265 mg tablet twice daily (BID).

ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID

Andra namn:
  • valiltramipros
  • tramiprosatprocess

Placebo tablet BID

Placebo-jämförare: Placebo

Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study

Placebo tablet BID

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Primary Cognitive Efficacy Endpoint (ADAS-Cog13)
Tidsram: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) scores.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)
Tidsram: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs leading to withdrawal.

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Key Secondary Endpoint (A-IADL-W)
Tidsram: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
Key Secondary Endpoint (CDR-SB)
Tidsram: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD)
Tidsram: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE)
Tidsram: Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Imaging Biomarker Endpoint (Hippocampal Volume)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Whole Cortex])
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Mayo Index])
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe.

Baseline to Week 78
Imaging Biomarker Endpoint (Whole Brain Volume)
Tidsram: Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint (Ventricular Volume)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in Grey Matter Mean Diffusivity - Bilateral Caudate
Tidsram: Baseline to Week 78

Change from baseline in Grey Matter Mean Diffusivity (Bilateral Caudate) as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in White Matter Mean Diffusivity (Bilateral Fornix)
Tidsram: Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Mean Diffusivity as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - White Matter Fractional Anisotropy (Bilateral Fornix)
Tidsram: Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Fractional Anisotropy as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). Fractional anisotropy (FA) is a unitless, scalar value that measures the degree of anisotropic (directional) water diffusion within a voxel, ranging from 0 to 1. A value of 0 indicates perfectly isotropic (equal in all directions) diffusion, while a value of 1 indicates perfectly anisotropic (directional) diffusion. Higher FA value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as higher FA in the ALZ-801 group compared with the placebo group.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - MCI Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Mild Alzheimer's Disease(Mild AD) Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - MCI Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Mild AD Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - MCI Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Mild AD Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - MCI Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Mild AD Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE) - MCI Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Global Cognition Assessment (MMSE) - Mild AD Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Hippocampal Volume (MCI Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Hippocampal Volume (Mild AD Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (MCI Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (Mild AD Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Mayo Index) (MCI Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Cortical Thickness (Mayo Index) (Mild AD Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Whole Brain Volume (MCI Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Whole Brain Volume (Mild AD Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (MCI Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (Mild AD Subgroup)
Tidsram: Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Female Subgroup of the FAS
Tidsram: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Male Subgroup of the FAS
Tidsram: Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - Female Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Male Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - Female Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Male Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - Female Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Male Subgroup
Tidsram: Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Treatment Emergent Adverse Events (TEAE) - Females
Tidsram: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
Treatment Emergent Adverse Events (TEAE) - Males
Tidsram: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Susan Abushakra, MD, Alzheon Inc.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

19 maj 2021

Primärt slutförande (Faktisk)

29 maj 2024

Avslutad studie (Faktisk)

29 juli 2024

Studieregistreringsdatum

Först inskickad

22 februari 2021

Först inskickad som uppfyllde QC-kriterierna

22 februari 2021

Första postat (Faktisk)

25 februari 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • ALZ-801-AD301
  • R01AG065253 (U.S.S. NIH-anslag/kontrakt)
  • 2020-005755-20 (EudraCT-nummer)

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera